ADMA BIOLOGICS INC (ADMA) Fundamental Analysis & Valuation

NASDAQ:ADMA • US0008991046

Current stock price

10.65 USD
+0.16 (+1.53%)
At close:
10.7312 USD
+0.08 (+0.76%)
After Hours:

This ADMA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. ADMA Profitability Analysis

1.1 Basic Checks

  • In the past year ADMA was profitable.
  • In the past year ADMA had a positive cash flow from operations.
  • In multiple years ADMA reported negative net income over the last 5 years.
  • In multiple years ADMA reported negative operating cash flow during the last 5 years.
ADMA Yearly Net Income VS EBIT VS OCF VS FCFADMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M

1.2 Ratios

  • ADMA's Return On Assets of 23.54% is amongst the best of the industry. ADMA outperforms 96.51% of its industry peers.
  • ADMA has a better Return On Equity (30.78%) than 96.71% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 27.76%, ADMA belongs to the top of the industry, outperforming 98.84% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for ADMA is significantly below the industry average of 27.73%.
  • The last Return On Invested Capital (27.76%) for ADMA is above the 3 year average (20.20%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 23.54%
ROE 30.78%
ROIC 27.76%
ROA(3y)18.47%
ROA(5y)2.12%
ROE(3y)22.18%
ROE(5y)-5.51%
ROIC(3y)20.2%
ROIC(5y)N/A
ADMA Yearly ROA, ROE, ROICADMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 400

1.3 Margins

  • The Profit Margin of ADMA (28.80%) is better than 93.99% of its industry peers.
  • With an excellent Operating Margin value of 37.52%, ADMA belongs to the best of the industry, outperforming 96.71% of the companies in the same industry.
  • Looking at the Gross Margin, with a value of 57.39%, ADMA is in the better half of the industry, outperforming 76.36% of the companies in the same industry.
  • In the last couple of years the Gross Margin of ADMA has grown nicely.
Industry RankSector Rank
OM 37.52%
PM (TTM) 28.8%
GM 57.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y35.81%
GM growth 5YN/A
ADMA Yearly Profit, Operating, Gross MarginsADMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. ADMA Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), ADMA is creating value.
  • Compared to 1 year ago, ADMA has more shares outstanding
  • ADMA has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, ADMA has an improved debt to assets ratio.
ADMA Yearly Shares OutstandingADMA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
ADMA Yearly Total Debt VS Total AssetsADMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • ADMA has an Altman-Z score of 12.43. This indicates that ADMA is financially healthy and has little risk of bankruptcy at the moment.
  • With an excellent Altman-Z score value of 12.43, ADMA belongs to the best of the industry, outperforming 83.14% of the companies in the same industry.
  • ADMA has a debt to FCF ratio of 2.62. This is a good value and a sign of high solvency as ADMA would need 2.62 years to pay back of all of its debts.
  • ADMA has a Debt to FCF ratio of 2.62. This is amongst the best in the industry. ADMA outperforms 93.02% of its industry peers.
  • ADMA has a Debt/Equity ratio of 0.15. This is a healthy value indicating a solid balance between debt and equity.
  • ADMA's Debt to Equity ratio of 0.15 is on the low side compared to the rest of the industry. ADMA is outperformed by 64.92% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF 2.62
Altman-Z 12.43
ROIC/WACC3
WACC9.25%
ADMA Yearly LT Debt VS Equity VS FCFADMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • ADMA has a Current Ratio of 6.71. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
  • ADMA has a Current ratio of 6.71. This is in the better half of the industry: ADMA outperforms 66.09% of its industry peers.
  • ADMA has a Quick Ratio of 3.74. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 3.74, ADMA perfoms like the industry average, outperforming 48.26% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.71
Quick Ratio 3.74
ADMA Yearly Current Assets VS Current LiabilitesADMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. ADMA Growth Analysis

3.1 Past

  • ADMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.00%, which is quite good.
  • The Revenue has grown by 19.63% in the past year. This is quite good.
  • ADMA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 64.62% yearly.
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.86%
Revenue 1Y (TTM)19.63%
Revenue growth 3Y49.04%
Revenue growth 5Y64.62%
Sales Q2Q%18.39%

3.2 Future

  • ADMA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.23% yearly.
  • ADMA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 19.85% yearly.
EPS Next Y62.35%
EPS Next 2Y43.82%
EPS Next 3Y40.03%
EPS Next 5Y35.23%
Revenue Next Year24.85%
Revenue Next 2Y23.47%
Revenue Next 3Y22.77%
Revenue Next 5Y19.85%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ADMA Yearly Revenue VS EstimatesADMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
ADMA Yearly EPS VS EstimatesADMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2

More info and screens

Find the best growth stocksShow best growing peers

8

4. ADMA Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 17.75, ADMA is valued on the expensive side.
  • Based on the Price/Earnings ratio, ADMA is valued cheaper than 94.38% of the companies in the same industry.
  • ADMA is valuated rather cheaply when we compare the Price/Earnings ratio to 27.38, which is the current average of the S&P500 Index.
  • The Price/Forward Earnings ratio is 10.93, which indicates a very decent valuation of ADMA.
  • Based on the Price/Forward Earnings ratio, ADMA is valued cheaper than 98.06% of the companies in the same industry.
  • ADMA's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 38.20.
Industry RankSector Rank
PE 17.75
Fwd PE 10.93
ADMA Price Earnings VS Forward Price EarningsADMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ADMA is valued cheaper than 95.16% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of ADMA indicates a rather cheap valuation: ADMA is cheaper than 91.47% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 92.22
EV/EBITDA 12.44
ADMA Per share dataADMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5 2

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of ADMA may justify a higher PE ratio.
  • ADMA's earnings are expected to grow with 40.03% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.28
PEG (5Y)N/A
EPS Next 2Y43.82%
EPS Next 3Y40.03%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ADMA Dividend Analysis

5.1 Amount

  • No dividends for ADMA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ADMA Fundamentals: All Metrics, Ratios and Statistics

ADMA BIOLOGICS INC

NASDAQ:ADMA (4/15/2026, 8:00:00 PM)

After market: 10.7312 +0.08 (+0.76%)

10.65

+0.16 (+1.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)05-05
Inst Owners93.43%
Inst Owner Change-0.08%
Ins Owners2.43%
Ins Owner Change1.12%
Market Cap2.54B
Revenue(TTM)510.17M
Net Income(TTM)146.93M
Analysts80
Price Target23.97 (125.07%)
Short Float %9.69%
Short Ratio3.81
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.01%
Min EPS beat(2)-1.96%
Max EPS beat(2)5.99%
EPS beat(4)1
Avg EPS beat(4)-7.27%
Min EPS beat(4)-31.17%
Max EPS beat(4)5.99%
EPS beat(8)4
Avg EPS beat(8)9.68%
EPS beat(12)6
Avg EPS beat(12)-7.7%
EPS beat(16)8
Avg EPS beat(16)-5.55%
Revenue beat(2)1
Avg Revenue beat(2)-0.66%
Min Revenue beat(2)-2.13%
Max Revenue beat(2)0.81%
Revenue beat(4)1
Avg Revenue beat(4)-1.78%
Min Revenue beat(4)-3.31%
Max Revenue beat(4)0.81%
Revenue beat(8)5
Avg Revenue beat(8)3.94%
Revenue beat(12)9
Avg Revenue beat(12)4.07%
Revenue beat(16)13
Avg Revenue beat(16)4.88%
PT rev (1m)-8.44%
PT rev (3m)-8.44%
EPS NQ rev (1m)2.63%
EPS NQ rev (3m)2.63%
EPS NY rev (1m)5.52%
EPS NY rev (3m)8.52%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.93%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.87%
Valuation
Industry RankSector Rank
PE 17.75
Fwd PE 10.93
P/S 4.97
P/FCF 92.22
P/OCF 50.33
P/B 5.31
P/tB 5.36
EV/EBITDA 12.44
EPS(TTM)0.6
EY5.63%
EPS(NY)0.97
Fwd EY9.15%
FCF(TTM)0.12
FCFY1.08%
OCF(TTM)0.21
OCFY1.99%
SpS2.14
BVpS2
TBVpS1.99
PEG (NY)0.28
PEG (5Y)N/A
Graham Number5.2016 (-51.16%)
Profitability
Industry RankSector Rank
ROA 23.54%
ROE 30.78%
ROCE 34.51%
ROIC 27.76%
ROICexc 32.97%
ROICexgc 33.27%
OM 37.52%
PM (TTM) 28.8%
GM 57.39%
FCFM 5.39%
ROA(3y)18.47%
ROA(5y)2.12%
ROE(3y)22.18%
ROE(5y)-5.51%
ROIC(3y)20.2%
ROIC(5y)N/A
ROICexc(3y)25.15%
ROICexc(5y)N/A
ROICexgc(3y)25.44%
ROICexgc(5y)N/A
ROCE(3y)25.11%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y35.81%
GM growth 5YN/A
F-Score6
Asset Turnover0.82
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF 2.62
Debt/EBITDA 0.35
Cap/Depr 282.75%
Cap/Sales 4.49%
Interest Coverage 21.09
Cash Conversion 25.26%
Profit Quality 18.72%
Current Ratio 6.71
Quick Ratio 3.74
Altman-Z 12.43
F-Score6
WACC9.25%
ROIC/WACC3
Cap/Depr(3y)149.71%
Cap/Depr(5y)178.08%
Cap/Sales(3y)2.81%
Cap/Sales(5y)6.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.86%
EPS Next Y62.35%
EPS Next 2Y43.82%
EPS Next 3Y40.03%
EPS Next 5Y35.23%
Revenue 1Y (TTM)19.63%
Revenue growth 3Y49.04%
Revenue growth 5Y64.62%
Sales Q2Q%18.39%
Revenue Next Year24.85%
Revenue Next 2Y23.47%
Revenue Next 3Y22.77%
Revenue Next 5Y19.85%
EBIT growth 1Y37.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year94.51%
EBIT Next 3Y44.53%
EBIT Next 5Y35.13%
FCF growth 1Y-75.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-57.53%
OCF growth 3YN/A
OCF growth 5YN/A

ADMA BIOLOGICS INC / ADMA Fundamental Analysis FAQ

What is the fundamental rating for ADMA stock?

ChartMill assigns a fundamental rating of 6 / 10 to ADMA.


What is the valuation status for ADMA stock?

ChartMill assigns a valuation rating of 8 / 10 to ADMA BIOLOGICS INC (ADMA). This can be considered as Undervalued.


Can you provide the profitability details for ADMA BIOLOGICS INC?

ADMA BIOLOGICS INC (ADMA) has a profitability rating of 7 / 10.


What is the valuation of ADMA BIOLOGICS INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for ADMA BIOLOGICS INC (ADMA) is 17.75 and the Price/Book (PB) ratio is 5.31.


How financially healthy is ADMA BIOLOGICS INC?

The financial health rating of ADMA BIOLOGICS INC (ADMA) is 7 / 10.